医学
Copeptin蛋白
内科学
危险系数
肺癌
生物标志物
利钠肽
前瞻性队列研究
随机对照试验
队列
四分位数
肿瘤科
加压素
心力衰竭
置信区间
化学
生物化学
作者
Emelie Gezelius,Pär‐Ola Bendahl,Widet Gallo,Kelin Gonçalves de Oliveira,Lars Ek,Bengt Bergman,Jan Sundberg,Olle Melander,Mattias Belting
出处
期刊:Cancers
[MDPI AG]
日期:2022-03-03
卷期号:14 (5): 1307-1307
被引量:1
标识
DOI:10.3390/cancers14051307
摘要
Cardiovascular comorbidity is common in small cell lung cancer (SCLC) and may significantly affect treatment tolerability and patient outcome. Still, there are no established biomarkers for objective and dynamic assessment as a tool for improved treatment decisions. We have investigated circulating levels of midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial-natriuretic peptide (MR-proANP), copeptin (surrogate for vasopressin) and suppression-of-tumorigenicity-2 (ST2), all known to correlate with various aspects of cardiovascular function, in a SCLC cohort (N = 252) from a randomized, controlled trial (RASTEN). For all measured biomarkers, protein levels were inversely associated with survival, particularly with ST2 and MR-proADM, where the top versus bottom quartile was associated with an adjusted hazard ratio of 2.40 (95% CI 1.44−3.98; p = 0.001) and 2.18 (95% CI 1.35−3.51; p = 0.001), respectively, in the entire cohort, and 3.43 (95% CI 1.73−6.79; p < 0.001) and 3.49 (95% CI 1.84−6.60; p < 0.001), respectively, in extensive disease patients. A high combined score of MR-proADM and ST2 was associated with a significantly reduced median OS of 7.0 months vs. 14.9 months for patients with a low combined score. We conclude that the cardiovascular biomarkers MR-proADM and ST2 strongly correlate with survival in SCLC, warranting prospective studies on the clinical utility of MR-proADM and ST2 for improved, individualized treatment decisions.
科研通智能强力驱动
Strongly Powered by AbleSci AI